Research & Analysis

Articles & Guides

Expert analysis, comparisons, and ranked listicles to help you evaluate pharmaceutical services vendors.

58 analyses · updated weekly

Editor's picks

Featured
Comparison Top 4

Best Hub Services Platforms: ConnectiveRx vs AssistRx vs CareMetx vs EVERSANA

Head-to-head hub platform comparison for manufacturers deciding whether ConnectiveRx, AssistRx, CareMetx, or EVERSANA best fits the patient-access operating model.

Read analysis →
Featured
Industry Analysis Apr 7, 2026

Hub Services Market Analysis: U.S. Pharmaceutical Patient Support Programs

U.S. hub services landscape analysis covering market-size caveats, competitive tiers, M&A, technology shifts, and buyer implications for pharma patient-support programs.

16 min read Covers 21 vendors
Featured
Industry Analysis Apr 8, 2026

Hub Services Buyer's Guide 2026: Complete Vendor Evaluation Framework

Practical RFP and diligence guide for evaluating hub services vendors across technology, operations, access support, affordability, clinical services, reporting, compliance, implementation, and contract protections.

15 min read Covers 6 vendors

Browse by topic

Organized across four super-categories of pharma commercial services.

Patient Access & Support

45 articles

Industry Analysis May 24, 2026

340B TPA Comparison: Apexus vs Sentry Data Systems vs Macro Helix

Covered-entity 340B TPA comparison for Apexus, Sentry Data Systems, and Macro Helix, with manufacturer channel-risk implications.

6 min read Covers 4 vendors
Industry Analysis May 24, 2026

Cell and Gene Therapy Services Comparison: Orsini vs PANTHERx vs Onco360 vs Accredo vs CVS

This comparison supports a manufacturer-side CGT launch decision: which specialty-pharmacy and access partner can handle product-specific requirements around cryogenic handling, REMS, treatment-center coordination, payer access, hub orchestration, and long-term follow-up.

6 min read Covers 5 vendors
Industry Analysis May 24, 2026

Oncology Pharmacy Network Design: LDD Segmentation and Specialty Pharmacy Selection

This analysis gives manufacturer launch teams a practical oncology specialty pharmacy network design framework: when to use Onco360, when to include PBM-owned SPs, when health-system pharmacies matter, and when independent specialists or rare-disease pharmacies should be in the network.

5 min read Covers 8 vendors
Explore Patient Access & Support

Commercialization & Market Access

6 articles

Industry Analysis May 24, 2026

Field Force Outsourcing Comparison: Syneos vs EVERSANA vs Trinity vs Inizio vs Amplity

This analysis supports a manufacturer decision on outsourced field teams, field reimbursement managers, medical science liaisons, nurse educators, and adjacent commercialization operations.

6 min read Covers 6 vendors
Industry Analysis Apr 19, 2026

PBM Transparency & Pass-Through Economics

Big 3 PBM opacity economics — spread pricing, rebate retention, self-preferencing to affiliated specialty pharmacies — face the most serious structural threat since the modern PBM model emerged in the early 2000s.

12 min read Covers 2 vendors
Comparison Apr 17, 2026

Market Access Consulting Deep Dive: Pricing, GTN, IRA Modeling, and How Top Firms Differ in 2026

Deep dive on market access consulting: firm tiers, typical engagement pricing, IRA MFP modeling, GTN waterfall work, and how Trinity, Avalere, Precision AQ, ZS, Bain, and others differ.

16 min read Covers 8 vendors
Explore Commercialization & Market Access

Clinical, Regulatory & Evidence

4 articles

Comparison Apr 20, 2026

Pharmacovigilance Safety Systems: Oracle Argus vs ArisGlobal vs Veeva Vault Safety

Head-to-head buyer comparison of the three most important pharmacovigilance system archetypes in the wiki today: the incumbent installed-base leader, the pure-play modernization specialist, and the broader platform-consolidation challenger.

5 min read Covers 5 vendors
Guide Apr 17, 2026

Regulatory Consulting for Pharma: FDA Submission Support, REMS, and Post-Market Surveillance

Guide to pharma regulatory consulting firms. Scope, firm tiers (scale CROs, boutiques, law-adjacent), day rates, engagement models, REMS, PVG, and when to choose which partner.

14 min read Covers 6 vendors
Guide Apr 16, 2026

Medical Affairs & MSL Outsourcing: Build vs Buy for Pharma Launch Teams

Build vs buy framework for pharma medical affairs and MSL deployment. Cost benchmarks, vendor comparison across Inizio, Syneos, Indegene, EVERSANA, Lumanity, and Red Nucleus.

15 min read Covers 12 vendors
Explore Clinical, Regulatory & Evidence

Supply Chain, Technology & Engagement

3 articles

Industry Analysis Apr 20, 2026

Pharma Commercial Technology & CRM Market Analysis

Analysis of the pharmaceutical commercial technology and CRM market — the software and data infrastructure powering field sales, HCP engagement, medical affairs, and omnichannel marketing for life sciences companies. The market is defined by Veeva Systems' structural dominance, the once-in-a-generation Salesforce platform migration, and the emerging AI disruption that could reshape the competitive landscape by 2030.

12 min read Covers 9 vendors
Comparison Apr 20, 2026

Veeva Vault CRM vs Salesforce Life Sciences Cloud: 2026 Buyer's Guide

Buyer comparison of the two main pharma commercial CRM paths in 2026, focused on migration risk, platform fit, and total-cost trade-offs.

21 min read Covers 10 vendors
Industry Analysis Apr 17, 2026

Contract Development & Manufacturing Organizations (CDMOs): Cold Chain, Cell & Gene, Biologic Fill-Finish in 2026

CDMO market sizing, tiered competitive landscape, BIOSECURE Act implications, cell/gene and fill-finish capacity, and a selection framework for biotech launch teams evaluating manufacturing partners.

15 min read Covers 6 vendors
Explore Supply Chain, Technology & Engagement

All articles

58 showing

Industry Analysis May 24, 2026

340B TPA Comparison: Apexus vs Sentry Data Systems vs Macro Helix

Covered-entity 340B TPA comparison for Apexus, Sentry Data Systems, and Macro Helix, with manufacturer channel-risk implications.

6 min read Covers 4 vendors
Industry Analysis May 24, 2026

Cell and Gene Therapy Services Comparison: Orsini vs PANTHERx vs Onco360 vs Accredo vs CVS

This comparison supports a manufacturer-side CGT launch decision: which specialty-pharmacy and access partner can handle product-specific requirements around cryogenic handling, REMS, treatment-center coordination, payer access, hub orchestration, and long-term follow-up.

6 min read Covers 5 vendors
Industry Analysis May 24, 2026

Field Force Outsourcing Comparison: Syneos vs EVERSANA vs Trinity vs Inizio vs Amplity

This analysis supports a manufacturer decision on outsourced field teams, field reimbursement managers, medical science liaisons, nurse educators, and adjacent commercialization operations.

6 min read Covers 6 vendors
Industry Analysis May 24, 2026

Oncology Pharmacy Network Design: LDD Segmentation and Specialty Pharmacy Selection

This analysis gives manufacturer launch teams a practical oncology specialty pharmacy network design framework: when to use Onco360, when to include PBM-owned SPs, when health-system pharmacies matter, and when independent specialists or rare-disease pharmacies should be in the network.

5 min read Covers 8 vendors
Industry Analysis May 24, 2026

State Prior Authorization Reform Tracker: Gold Carding, CMS-0057, and Vendor Implications

State prior authorization reform tracker for pharma services vendors, covering gold carding, CMS-0057-F interplay, and vendor implications.

4 min read Covers 8 vendors
Industry Analysis Apr 22, 2026

Digital Access Operating Models: Affordability, Hub, and Direct-to-Patient

Buyer guide to pharma digital access models across affordability, hub, and DTP programs, comparing TailorMed, RIS Rx, BlinkRx, Phil, Gifthealth, Fuze Health, Atlantis Health, and IntegriChain.

8 min read Covers 8 vendors
Industry Analysis Apr 20, 2026

AI Disruption in Pharma Services: Market Structure Implications

AI will change pharma services economics first by compressing routine administrative labor, not by replacing the full hub, specialty-pharmacy, or patient-services operating model. The strongest current use cases are high-volume PA, BV, document intake, payer-status calls, and workflow triage; the weakest are clinical counseling, rare-disease judgment, CGT coordination, and accountable patient support.

10 min read Covers 13 vendors
Industry Analysis Apr 20, 2026

AI Prior Authorization Platform Comparison: Six Vendors Reshaping PA Automation

Head-to-head analysis of six AI-native prior authorization platforms — Infinitus Systems, Tandem AI, Cohere Health, Coral AI, Neon Health, and SuperDial — spanning voice AI, document AI, and agentic workflow architectures, with implications for CMS-0057-F compliance and pharma manufacturer hub operations.

17 min read Covers 12 vendors
Industry Analysis Apr 20, 2026

Big Three PBM Specialty Pharmacy Operations

The Big Three PBM specialty pharmacies are not simply large dispensing vendors; they are vertically integrated control points that combine formulary leverage, network steering, specialty fulfillment, copay/maximizer economics, and private-label biosimilar strategy.

12 min read Covers 10 vendors
Industry Analysis Apr 20, 2026

CMS-0057-F Vendor Readiness Matrix: Who's Ready for January 2027

CMS-0057-F turns prior authorization interoperability from a policy aspiration into a dated procurement event. The winners are not simply vendors that can say "FHIR" in a sales deck; they are vendors with production payer deployments, coverage across the relevant Da Vinci implementation guides, integration paths into core admin and provider workflows, and enough decisioning logic to improve actual PA cycle time.

16 min read Covers 8 vendors
Industry Analysis Apr 20, 2026

Pharma Commercial Technology & CRM Market Analysis

Analysis of the pharmaceutical commercial technology and CRM market — the software and data infrastructure powering field sales, HCP engagement, medical affairs, and omnichannel marketing for life sciences companies. The market is defined by Veeva Systems' structural dominance, the once-in-a-generation Salesforce platform migration, and the emerging AI disruption that could reshape the competitive landscape by 2030.

12 min read Covers 9 vendors
Comparison Apr 20, 2026

Health System SP Accelerators: Shields vs Clearway Health vs CarePathRx vs CPS Solutions

Buyer comparison of the four most relevant health-system specialty pharmacy accelerators in 2026, focused on independence, stack breadth, and structural channel risk.

6 min read Covers 2 vendors
Industry Analysis Apr 20, 2026

Health System Specialty Pharmacy: Build vs. Buy vs. Partner

The 2019-2023 "build your own specialty pharmacy" playbook for health systems no longer describes the 2026 decision. The defining event reframing the calculus was originally Walgreens' August 28, 2025 divestiture of Shields Health Solutions to Sycamore Partners, financed in part by $3.5B of preferred equity from Evernorth (Cigna/Express Scripts). But that event did not stand alone.

15 min read Covers 8 vendors
Industry Analysis Apr 20, 2026

US Pharma Services Market Sizing and 2025 Update

Directional U.S. pharma services market sizing across specialty pharmacy, prior authorization and reimbursement support, copay programs, market access consulting, data/RWE, and commercial technology, with the 2025 banking-report update folded into one public market map.

18 min read Covers 31 vendors
Comparison Apr 20, 2026

Pharmacovigilance Safety Systems: Oracle Argus vs ArisGlobal vs Veeva Vault Safety

Head-to-head buyer comparison of the three most important pharmacovigilance system archetypes in the wiki today: the incumbent installed-base leader, the pure-play modernization specialist, and the broader platform-consolidation challenger.

5 min read Covers 5 vendors
Industry Analysis Apr 20, 2026

Specialty Pharmacy Competitive Landscape

U.S. specialty pharmacy landscape analysis covering PBM-owned scale platforms, independent clinical specialists, and health-system specialty pharmacy growth.

8 min read Covers 7 vendors
Comparison Apr 20, 2026

Veeva Vault CRM vs Salesforce Life Sciences Cloud: 2026 Buyer's Guide

Buyer comparison of the two main pharma commercial CRM paths in 2026, focused on migration risk, platform fit, and total-cost trade-offs.

21 min read Covers 10 vendors
Industry Analysis Apr 19, 2026

PBM Transparency & Pass-Through Economics

Big 3 PBM opacity economics — spread pricing, rebate retention, self-preferencing to affiliated specialty pharmacies — face the most serious structural threat since the modern PBM model emerged in the early 2000s.

12 min read Covers 2 vendors
Comparison Apr 17, 2026

Big-3 Specialty Pharmacy: CVS Specialty vs Accredo vs OptumRx Specialty

Head-to-head comparison of the three PBM-owned specialty pharmacies that collectively dispense ~66% of U.S. specialty drug revenue.

16 min read Covers 9 vendors
Industry Analysis Apr 17, 2026

Contract Development & Manufacturing Organizations (CDMOs): Cold Chain, Cell & Gene, Biologic Fill-Finish in 2026

CDMO market sizing, tiered competitive landscape, BIOSECURE Act implications, cell/gene and fill-finish capacity, and a selection framework for biotech launch teams evaluating manufacturing partners.

15 min read Covers 6 vendors
Comparison Apr 17, 2026

Home Infusion Platforms: CVS Coram vs Option Care Health vs Naven Health

Head-to-head comparison of the three dominant home and alternate-site infusion models biotech commercialization teams evaluate when planning IV/SC biologic launches.

12 min read Covers 4 vendors
Comparison Apr 17, 2026

Market Access Consulting Deep Dive: Pricing, GTN, IRA Modeling, and How Top Firms Differ in 2026

Deep dive on market access consulting: firm tiers, typical engagement pricing, IRA MFP modeling, GTN waterfall work, and how Trinity, Avalere, Precision AQ, ZS, Bain, and others differ.

16 min read Covers 8 vendors
Guide Apr 17, 2026

Regulatory Consulting for Pharma: FDA Submission Support, REMS, and Post-Market Surveillance

Guide to pharma regulatory consulting firms. Scope, firm tiers (scale CROs, boutiques, law-adjacent), day rates, engagement models, REMS, PVG, and when to choose which partner.

14 min read Covers 6 vendors
Industry Analysis Apr 16, 2026

340B Contract Pharmacy Restrictions: What Manufacturers and Vendors Need to Know in 2026

2026 field guide to 340B contract pharmacy restrictions: manufacturer policies, Eighth/Third/D.C. Circuit rulings, state laws, the vacated rebate pilot, and vendor selection impact.

16 min read Covers 15 vendors
Industry Analysis Apr 16, 2026

Cell & Gene Therapy Commercialization: The Services Landscape in 2026

The CGT vendor stack is categorically different from specialty biologics. FACT sites, cryo-chain logistics, one-time pricing, and outcomes-based contracts reshape every service line.

17 min read Covers 23 vendors
Comparison Apr 16, 2026

Contract Sales Organizations (CSOs) for Pharma: Syneos vs Inizio vs Publicis vs Indegene Comparison

Head-to-head comparison of the major contract sales organizations serving pharma: Syneos Health, Inizio Engage, Publicis Health, Indegene, and EVERSANA.

16 min read Covers 5 vendors
Comparison Top 4 Apr 16, 2026

Pharma Copay Program Vendors: ConnectiveRx vs Valeris vs Phil vs Apollo Care

Head-to-head comparison of four copay and financial assistance platforms for pharmaceutical manufacturers. Spans legacy per-redemption processors to digital-first orchestration.

19 min read Covers 4 vendors
Guide Apr 16, 2026

Field Reimbursement Managers (FRMs): What They Do, Cost, and How to Deploy

Operator guide to FRM programs: functions, loaded-cost modeling, territory sizing, deployment vendors, hub integration, and ROI measurement for specialty launches.

17 min read Covers 9 vendors
Industry Analysis Top 7 Apr 16, 2026

GLP-1 Services Crunch: Which Pharma Services Vendors Scale to 10M Patients?

Institutional analysis of which pharma services vendors can scale to GLP-1 volumes. Hubs, AI-PA, retail shift, DTC/telehealth, compounding, and the 2027 IRA reset.

22 min read Covers 19 vendors
Industry Analysis Apr 16, 2026

IRA Maximum Fair Price: What Rounds 2-3 Mean for Hub, Copay, and Specialty Pharmacy Vendors

How IRA Medicare negotiation Rounds 2-3 (2027-2028 MFPs) restructure vendor economics across hubs, copay, specialty pharmacy, 340B, and market access consulting.

19 min read Covers 19 vendors
Guide Apr 16, 2026

Medical Affairs & MSL Outsourcing: Build vs Buy for Pharma Launch Teams

Build vs buy framework for pharma medical affairs and MSL deployment. Cost benchmarks, vendor comparison across Inizio, Syneos, Indegene, EVERSANA, Lumanity, and Red Nucleus.

15 min read Covers 12 vendors
Guide Apr 16, 2026

Oncology Launch: Vendor Stack Playbook for Commercial Teams

The vendor stack for an oncology launch: hub services, specialty pharmacy, field reimbursement, RWE, and medical affairs, mapped by route of administration.

16 min read Covers 25 vendors
Industry Analysis Apr 16, 2026

Part D Redesign 2025-2026: The End of Copay Accumulators and the New Patient Economics

How the 2025 Part D redesign, $2,000 OOP cap, Manufacturer Discount Program, and smoothing rewrite manufacturer economics and neutralize accumulator value.

12 min read Covers 17 vendors
Industry Analysis Apr 16, 2026

PBM Reform 2026: What CAA, FTC, State Divestitures, and Transparency Rules Mean for Pharma Vendor Strategy

How the FTC Express Scripts settlement, CAA 2026, Arkansas Act 624, and federal delinking proposals are reshaping specialty pharmacy, hub services, and manufacturer GTN strategy.

15 min read Covers 11 vendors
Guide Apr 16, 2026

Pharma Services Explained: Hub, Specialty Pharmacy, FRM, and How They Fit Together

Lexicon guide to the pharma commercial services stack. Hub vs specialty pharmacy vs field reimbursement vs copay processor vs market access, with pricing models and named vendors.

16 min read Covers 18 vendors
Guide Apr 16, 2026

Rare Disease Launch: Vendor Stack Playbook

A prescriptive vendor-stack playbook for rare disease launch teams — sequenced T-18 to T+6 with named vendors, pricing benchmarks, and decision trade-offs for orphan drug commercialization.

22 min read Covers 16 vendors
Listicle Top 5 Apr 16, 2026

Top 12 Real-World Evidence (RWE) Vendors for Pharma in 2026

Ranking of the 12 leading real-world evidence vendors for pharma in 2026, covering claims, EHR, genomic, patient-reported, and integrated RWD providers.

19 min read Covers 5 vendors
Listicle Top 10 Apr 16, 2026

Top 10 Specialty Pharmacies for Pharma Manufacturers (2026)

Ranking and analysis of the top 10 specialty pharmacies serving pharma manufacturers, covering PBM-owned, independent, payer-owned, retail-adjacent, and health-system accelerator models.

18 min read Covers 12 vendors
Industry Analysis Apr 15, 2026

AI Hub Operations ROI: What Manufacturers Should Expect

Framework for evaluating AI hub operations ROI in pharma patient support: labor savings, time-to-therapy lift, abandonment reduction, quality risk, and savings pass-through.

6 min read Covers 6 vendors
Industry Analysis Apr 15, 2026

Biosimilar Launch Playbook: Hub, Copay & SP Strategy

Analysis of the hub services, copay assistance, and specialty pharmacy strategy specific to biosimilar launches — a structurally different commercial model from innovator biologics that requires recalibrated vendor selection, program design, and economic assumptions.

9 min read
Industry Analysis Apr 15, 2026

Health System Specialty Pharmacy Economics

Health system specialty pharmacies are the fastest-growing channel in specialty drug distribution, expanding from 15% to 27% of URAC-accredited SP locations between 2017 and 2024. The growth is driven by a single economic force: 340B Drug Pricing Program margin capture.

8 min read Covers 5 vendors
Industry Analysis Apr 15, 2026

Hub Services RFP Framework: What Pharma Buyers Evaluate

This analysis is synthesized from hub-services RFP requirements, public operating benchmarks, and vendor capability materials. It provides a comprehensive view of what pharmaceutical companies look for when selecting a hub services vendor -- essential context for understanding competitive dynamics and vendor differentiation in the hub market.

11 min read Covers 2 vendors
Industry Analysis Apr 15, 2026

Payer Landscape Overview: Plan Design, Self-Insured Dynamics & Formulary Strategies

Analysis of the U.S. commercial and government payer landscape as it relates to pharmaceutical services vendor selection. This page provides the demand-side context that shapes hub services, copay assistance, specialty pharmacy, and prior authorization vendor requirements.

14 min read Covers 8 vendors
Comparison Apr 15, 2026

Rare Disease SP Comparison: PANTHERx vs Orsini

Head-to-head comparison of the two leading independent rare disease specialty pharmacies in the United States. PANTHERx Rare and Orsini Specialty Pharmacy represent different approaches to the same niche: pure-play rare disease scale vs. integrated hub+SP+3PL with cell/gene therapy leadership. This comparison is the most important decision point for orphan drug manufacturers selecting a dedicated rare disease pharmacy partner.

10 min read Covers 4 vendors
Industry Analysis Apr 13, 2026

Conflict of Interest in Pharma Commercial Services: A Manufacturer's Framework

Conflict of interest is now a core vendor-selection variable in pharma commercialization, not a legal afterthought. PBM-owned specialty pharmacies, distributor-owned hubs, full-stack commercialization platforms, copay maximizer operators, and data-rich service vendors can all create value through integration, but the same integration can redirect prescriptions, obscure economics, constrain data rights, or weaken manufacturer control over the patient journey.

11 min read Covers 18 vendors
Industry Analysis Apr 13, 2026

CSO Market Post-Restructuring: Syneos, Inizio, and the New Competitive Order

The CSO market is moving away from pure field-force rental toward integrated commercialization, patient solutions, analytics, and flexible deployment. Syneos and Inizio still anchor the scale market, but both are reshaped by PE ownership, leverage, restructuring, and the permanent reduction in traditional in-person field demand.

11 min read Covers 7 vendors
Industry Analysis Apr 13, 2026

Hub Services Pricing Benchmarking: What Should Manufacturers Pay?

Hub pricing is opaque because vendors price capacity, transactions, patients, technology, and outcomes in different combinations, while manufacturers often benchmark proposals too late in the launch process. The practical thesis is that hub cost should be evaluated against workflow complexity and revenue impact, not against a generic rate card.

5 min read
Industry Analysis Apr 13, 2026

PBM-Owned vs Independent Specialty Pharmacy Competitive Analysis

PBM-owned specialty pharmacies dominate by structural control over formulary, network, and captive lives; independent and health-system specialty pharmacies compete on clinical depth, manufacturer alignment, data transparency, and limited-distribution execution. For manufacturers, the optimal network is therefore product-specific rather than ideology-specific.

9 min read Covers 4 vendors
Industry Analysis Apr 13, 2026

PBM Reform Implications for Pharma Services Vendors

PBM reform is accelerating across federal, state, and regulatory levels. The convergence of the FTC investigation, Consolidated Appropriations Act of 2026 (CAA), state PBM divestiture legislation, and copay accumulator/maximizer restrictions is reshaping the competitive landscape for every pharma services vendor category. This analysis maps the specific implications for hub services, specialty pharmacies, copay assistance vendors, and market access consultants.

9 min read Covers 10 vendors
Industry Analysis Apr 13, 2026

Therapeutic Area Specialization Guide: How Hub and SP Workflows Differ by Disease

Therapeutic area specialization is the most common source of false comparability in hub and specialty-pharmacy RFPs. Oncology, rare disease, autoimmune, GLP-1/metabolic, and CGT programs use overlapping vendor categories, but the work is fundamentally different: buy-and-bill versus pharmacy benefit, high-touch case management versus high-volume automation, oral adherence versus chain-of-identity logistics, and biosimilar/formulary defense versus patient finding.

11 min read Covers 9 vendors
Industry Analysis Apr 13, 2026

Vertical Integration Economics in Pharma Services

Vertical integration creates real operating value but transfers bargaining power and data control away from manufacturers. PBM/SP/insurer stacks, distributor/hub/pharmacy stacks, and full-stack commercialization platforms all promise fewer handoffs, richer data, and simpler accountability.

11 min read Covers 10 vendors
Comparison Top 2 Apr 9, 2026

AI Prior Authorization Vendors: Infinitus vs SuperDial vs Neon Health vs Coral AI

Head-to-head comparison of four AI-native prior authorization automation vendors targeting different segments of the pharma patient access workflow. Represents the emerging question of where AI inserts into the PA process: voice-based payer call automation (Infinitus, SuperDial), end-to-end multi-channel workflow orchestration (Neon Health), or pre-submission document AI (Coral AI).

10 min read Covers 7 vendors
Comparison Top 4 Apr 9, 2026

Data & Analytics Platforms: IQVIA vs Komodo Health vs Definitive Healthcare vs ConcertAI

Head-to-head comparison of the four dominant data and analytics platforms for pharma commercial operations. Represents the ecosystem question facing procurement teams: legacy incumbent (IQVIA) versus patient-journey challenger (Komodo Health) versus institutional intelligence specialist (Definitive Healthcare) versus oncology-specific AI platform (ConcertAI).

10 min read Covers 7 vendors
Comparison Top 4 Apr 9, 2026

Best Hub Services Platforms: ConnectiveRx vs AssistRx vs CareMetx vs EVERSANA

Head-to-head hub platform comparison for manufacturers deciding whether ConnectiveRx, AssistRx, CareMetx, or EVERSANA best fits the patient-access operating model.

11 min read Covers 6 vendors
Comparison Apr 8, 2026

ConnectiveRx vs EVERSANA: Hub Services Head-to-Head Comparison

Head-to-head comparison of ConnectiveRx and EVERSANA for hub services and patient support programs. Represents the core architectural question facing pharmaceutical buyers: focused specialist vs. full-stack commercialization partner.

7 min read Covers 4 vendors
Industry Analysis Apr 8, 2026

Hub Services Buyer's Guide 2026: Complete Vendor Evaluation Framework

Practical RFP and diligence guide for evaluating hub services vendors across technology, operations, access support, affordability, clinical services, reporting, compliance, implementation, and contract protections.

15 min read Covers 6 vendors
Industry Analysis Apr 7, 2026

Hub Services Market Analysis: U.S. Pharmaceutical Patient Support Programs

U.S. hub services landscape analysis covering market-size caveats, competitive tiers, M&A, technology shifts, and buyer implications for pharma patient-support programs.

16 min read Covers 21 vendors
Industry Analysis Apr 5, 2026

EVERSANA Patient Services: Full-Stack Commercialization Model

This analysis is derived from EVERSANA's Patient Services General Capabilities Deck (2024), a 49-page presentation detailing their integrated patient services and commercialization platform. EVERSANA represents the most complete example of a "full-stack" pharma commercialization partner -- a model that bundles advisory, field deployment, patient services, specialty pharmacy, market access, and data analytics under one roof.

9 min read Covers 2 vendors